Researchers at the Istituti Fisioterapici Ospitalieri (IFO) in Rome have claimed that Pfizer/BioNTech’s Coronavirus vaccine is less effective in people with obesity.
Over the course of the study, Italian researchers assessed the antibody response following two doses of the Pfizer vaccine in 248 healthcare workers.
HEC Approves New Ph.D. Program for Sindh Madressatul Islam University
According to the study, 99.5% of the healthcare workers had developed an antibody response after seven days following the second dose of the Pfizer vaccine.
However, obese healthcare workers produced only about half the amount of antibodies after receiving the second dose in comparison with healthy workers.
Aldo Venuti, the study’s co-author, has said that although it is too soon to know what this means for the efficacy of the vaccine, it might imply that people with obesity need an additional booster dose to ensure they are adequately protected against coronavirus.
Previous studies have also linked obesity with an increased risk of hospitalization, reinfection, and death due to Coronavirus.
In August last year, US researchers had claimed that obesity increases the risk of dying due to COVID-19 by 48% and hospitalization by 113%.
CAA Mandates Registration With Protector For Work Visa Holders
Another study revealed that obese people are at increased risk of getting reinfected from SARS-COV-2 than healthy people.
It is because obese people often have other underlying medical conditions, such as heart disease or type 2 diabetes, which put them at greater risk from the Coronavirus.
The excess body fat also causes significant metabolic changes, such as insulin resistance and inflammation, which make it harder for the body to fight off infections.